Viridian Therapeutics (VRDN)
(Delayed Data from NSDQ)
$15.40 USD
+0.82 (5.62%)
Updated May 3, 2024 04:00 PM ET
After-Market: $15.40 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
VRDN 15.40 +0.82(5.62%)
Will VRDN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for VRDN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VRDN
How Much Upside is Left in Viridian Therapeutics, Inc. (VRDN)? Wall Street Analysts Think 97.81%
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Tops Revenue Estimates
VRDN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Janux Therapeutics, Inc. (JANX) Moves 5.6% Higher: Will This Strength Last?
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Lags Revenue Estimates
Analysts Estimate Viridian Therapeutics, Inc. (VRDN) to Report a Decline in Earnings: What to Look Out for
Other News for VRDN
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024
Foghorn Therapeutics appoints Humer as Chief Financial Officer
Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME), Arvinas Holding Company (ARVN) and Viridian Therapeutics (VRDN)
Buy Rating Affirmed for Viridian Therapeutics Amidst TED Treatment Market Potential